Leigh Sundem1, Kuang-Ching Chris Tseng1, Haiyan Li1, John Ketz2, Mark Noble3, John Elfar4. 1. Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY. 2. Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY. 3. Department of Biomedical Genetics, Institute for Stem Cell and Regenerative Medicine, University of Rochester Medical Center, Rochester, NY. 4. Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY; Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY. Electronic address: openelfar@gmail.com.
Abstract
PURPOSE: We previously found that administration of erythropoietin (EPO) shortens the course of recovery after experimental crush injury to the mouse sciatic nerve. The course of recovery was more rapid than would be expected if EPO's effects were caused by axonal regeneration, which raised the question of whether recovery was instead the result of promoting remyelination and/or preserving myelin on injured neurons. This study tested the hypothesis that EPO has a direct and local effect on myelination in vivo and in vitro. METHODS: Animals were treated with EPO after standard calibrated sciatic nerve crush injury; immunohistochemical analysis was performed to assay for myelinated axons. Combined in vitro neuron-Schwann cell co-cultures were performed to assess EPO-mediated effects directly on myelination and putative protective effects against oxidative stress. In vivo local administration of EPO in a fibrin glue carrier was used to demonstrate early local effects of EPO treatment well in advance of possible neuroregenerative effects. RESULTS: Systemic Administration of EPO maintained more in vivo myelinated axons at the site of nerve crush injury. In vitro, EPO treatment promoted myelin formation and protected myelin from the effects of nitric oxide exposure in co-cultures of Schwann cells and dorsal root ganglion neurons. In a novel, surgically applicable local treatment using Food and Drug Administration-approved fibrin glue as a vehicle, EPO was as effective as systemic EPO administration at time points earlier than those explainable using standard models of neuroregeneration. CONCLUSIONS: In nerve crush injury, EPO may be exerting a primary influence on myelin status to promote functional recovery. CLINICAL RELEVANCE: Mixed injury to myelin and axons may allow the opportunity for the repurposing of EPO for use as a myeloprotective agent in which injuries spare a requisite number of axons to allow early functional recovery.
PURPOSE: We previously found that administration of erythropoietin (EPO) shortens the course of recovery after experimental crush injury to the mouse sciatic nerve. The course of recovery was more rapid than would be expected if EPO's effects were caused by axonal regeneration, which raised the question of whether recovery was instead the result of promoting remyelination and/or preserving myelin on injured neurons. This study tested the hypothesis that EPO has a direct and local effect on myelination in vivo and in vitro. METHODS: Animals were treated with EPO after standard calibrated sciatic nerve crush injury; immunohistochemical analysis was performed to assay for myelinated axons. Combined in vitro neuron-Schwann cell co-cultures were performed to assess EPO-mediated effects directly on myelination and putative protective effects against oxidative stress. In vivo local administration of EPO in a fibrin glue carrier was used to demonstrate early local effects of EPO treatment well in advance of possible neuroregenerative effects. RESULTS: Systemic Administration of EPO maintained more in vivo myelinated axons at the site of nerve crush injury. In vitro, EPO treatment promoted myelin formation and protected myelin from the effects of nitric oxide exposure in co-cultures of Schwann cells and dorsal root ganglion neurons. In a novel, surgically applicable local treatment using Food and Drug Administration-approved fibrin glue as a vehicle, EPO was as effective as systemic EPO administration at time points earlier than those explainable using standard models of neuroregeneration. CONCLUSIONS: In nerve crush injury, EPO may be exerting a primary influence on myelin status to promote functional recovery. CLINICAL RELEVANCE: Mixed injury to myelin and axons may allow the opportunity for the repurposing of EPO for use as a myeloprotective agent in which injuries spare a requisite number of axons to allow early functional recovery.
Authors: Masanori Iwai; R Anne Stetler; Juan Xing; Xiaoming Hu; Yanqin Gao; Wenting Zhang; Jun Chen; Guodong Cao Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: Giovanni Grasso; Alessandra Sfacteria; Marcello Passalacqua; Antonio Morabito; Michele Buemi; Battesimo Macrì; Michael L Brines; Francesco Tomasello Journal: Neurosurgery Date: 2005-04 Impact factor: 4.654
Authors: Yun Kyung Cho; Gunha Kim; Serah Park; Ju Hee Sim; You Jin Won; Chang Ho Hwang; Jong Yoon Yoo; Hea Nam Hong Journal: Biochem Biophys Res Commun Date: 2011-12-16 Impact factor: 3.575
Authors: W Marie Campana; Xiaoqing Li; Veronica I Shubayev; Mila Angert; Karen Cai; Robert R Myers Journal: Eur J Neurosci Date: 2006-02 Impact factor: 3.386
Authors: Max Modrak; M A Hassan Talukder; Khatuna Gurgenashvili; Mark Noble; John C Elfar Journal: J Neurosci Res Date: 2019-10-13 Impact factor: 4.164
Authors: Jung Il Lee; Ji Hun Park; Yeong-Rim Kim; Kihak Gwon; Hae Won Hwang; Gayoung Jung; Joo-Yup Lee; Jeong-Yun Sun; Jong Woong Park; Jae Ho Shin; Myoung-Ryul Ok Journal: Neural Regen Res Date: 2022-09 Impact factor: 5.135
Authors: Bruna Lopes; Patrícia Sousa; Rui Alvites; Mariana Branquinho; Ana Catarina Sousa; Carla Mendonça; Luís Miguel Atayde; Ana Lúcia Luís; Artur S P Varejão; Ana Colette Maurício Journal: Int J Mol Sci Date: 2022-01-14 Impact factor: 5.923